EUVIMEDOpdag EUVIMED
Crossref

Outcomes with alemtuzumab induction therapy in lung transplantation: a comprehensive large‐scale single‐center analysis

Alberto Benazzo, Sophia Auner, Panja M Boehm, Annika Morscher, Stefan Schwarz, Bogdan Vidmar, Fedja Dzubur, Thomas Schweiger, Ali M Hoda, Bernhard Moser, Jose R Matilla, Gabriella Muraközy and 5 more

Transplant International · 2021-12 · 34 (12) · 2633-2643

DOI: 10.1111/tri.14153 ↗

At a glance

Journal article in Transplant International, published online on 2021-11-16. Written by Alberto Benazzo and 16 co-authors. Institution: Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria. Major MEDLINE topics: Induction Chemotherapy, Lung Transplantation. Cited 19 times so far (Crossref); 26 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Alemtuzumab is a monoclonal antibody targeting CD52, increasingly used as induction therapy after transplantation. The aim of this study was to analyze the outcomes of alemtuzumab induction therapy followed by a low-dose maintenance immunosuppression in a large single-center cohort of lung transplant recipients. All patients, who received alemtuzumab induction followed by a low-dose maintenance immunosuppression were included in the analysis. Short- and long-term outcomes were analyzed. 721 lung transplant recipients, transplanted between January 2008 and June 2019, were included in this retrospective study. Freedom from higher-grade ACR at 1, 5, and 10 years was 98%, 96%, and 96%, respectively. Thirty-nine patients (5%) developed clinical AMR. Twenty-one percent of patients developed high-grade CKD. A total of 1488 infections were recorded. Sixteen percent were diagnosed within the first 3 months. Sixty-two patients (9%) developed a malignancy during follow-up. Freedom from CLAD at 1, 5, and 10 years was 94%, 72%, and 53%, respectively. Overall survival rates at 1, 5, and 10 years were 85%, 71%, and 61%, respectively. Alemtuzumab induction combined with a low-dose tacrolimus protocol is safe and associated with low rates of acute and chronic rejection, as well as an excellent long-term survival.

Subjects

MeSH terms (MEDLINE)

Induction ChemotherapyLung TransplantationAlemtuzumabAntibodies, Monoclonal, HumanizedGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsRetrospective Studies

Author keywords

alemtuzumabimmunosuppressioninduction therapylung transplantationrejection

Substances

Antibodies, Monoclonal, HumanizedImmunosuppressive AgentsAlemtuzumab

Authors and institutions

  • Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
  • Division of Thoracic Surgery, Medical Center Ljubljana, Ljubljana, Slovenia.
  • Clinical Center for Pulmonary Diseases, University Hospital Centre Zagreb, Zagreb, Croatia.

Cite

APA

Benazzo, A., Auner, S., Boehm, P. M., Morscher, A., Schwarz, S., Vidmar, B., Dzubur, F., Schweiger, T., Hoda, A. M., Moser, B., Matilla, J. R., Muraközy, G., Lang, G., Taghavi, S., Klepetko, W., Hoetzenecker, K., & Jaksch, P. (2021). Outcomes with alemtuzumab induction therapy in lung transplantation: a comprehensive large‐scale single‐center analysis. Transplant International, 34(12), 2633-2643. https://doi.org/10.1111/tri.14153

Vancouver

Benazzo A, Auner S, Boehm PM, Morscher A, Schwarz S, Vidmar B, et al. Outcomes with alemtuzumab induction therapy in lung transplantation: a comprehensive large‐scale single‐center analysis. Transplant International. 2021;34(12):2633-2643. doi:10.1111/tri.14153

BibTeX
@article{Benazzo2021,
  author = {Benazzo, Alberto and Auner, Sophia and Boehm, Panja M and Morscher, Annika and Schwarz, Stefan and Vidmar, Bogdan and Dzubur, Fedja and Schweiger, Thomas and Hoda, Ali M and Moser, Bernhard and Matilla, Jose R and Muraközy, Gabriella and Lang, Georg and Taghavi, Shahrokh and Klepetko, Walter and Hoetzenecker, Konrad and Jaksch, Peter},
  title = {Outcomes with alemtuzumab induction therapy in lung transplantation: a comprehensive large‐scale single‐center analysis},
  journal = {Transplant International},
  year = {2021},
  volume = {34},
  number = {12},
  pages = {2633--2643},
  doi = {10.1111/tri.14153}
}
Start for free →